Muscarinic M1 Receptor Modulation of Synaptic Plasticity in Nucleus Accumbens of Wild-Type and Fragile X Mice by Neuhofer, Daniela et al.
HAL Id: hal-02079467
https://hal.archives-ouvertes.fr/hal-02079467
Submitted on 26 Mar 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Muscarinic M1 Receptor Modulation of Synaptic
Plasticity in Nucleus Accumbens of Wild-Type and
Fragile X Mice
Daniela Neuhofer, Olivier Lassalle, Olivier Manzoni
To cite this version:
Daniela Neuhofer, Olivier Lassalle, Olivier Manzoni. Muscarinic M1 Receptor Modulation of Synaptic
Plasticity in Nucleus Accumbens of Wild-Type and Fragile X Mice. ACS Chemical Neuroscience,
American Chemical Society (ACS), 2018, 9 (9), pp.2233-2240. ￿10.1021/acschemneuro.7b00398￿. ￿hal-
02079467￿
Muscarinic M1 Receptor Modulation of Synaptic Plasticity in Nucleus
Accumbens of Wild-Type and Fragile X Mice
Daniela Neuhofer,*,†,‡,§,∥ Olivier Lassalle,†,‡,§ and Olivier J. Manzoni†,‡,§
†INMED, INSERM U901, 13273 Marseille, France
‡Aix-Marseille University, 13007 Marseille, France
§Universite ́ de Aix-Marseille, UMR S901, 13273 Marseille, France
∥Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina 29425, United States
*S Supporting Information
ABSTRACT: We investigated how metabotropic acetylcho-
line receptors control excitatory synaptic plasticity in the
mouse nucleus accumbens core. Pharmacological and genetic
approaches revealed that M1 mAChRs (muscarinic acetylcho-
line receptors) trigger multiple and interacting forms of
synaptic plasticity. As previously described in the dorsal
striatum, moderate pharmacological activation of M1 mAChR
potentiated postsynaptic NMDARs. The M1-potentiation of
NMDAR masked a previously unknown coincident TRPV1-
mediated long-term depression (LTD). In addition, strong
pharmacological activation of M1 mAChR induced canonical
retrograde LTD, mediated by presynaptic CB1R. In the fmr1-/
y mouse model of Fragile X, we found that CB1R but not
TRPV1 M1-LTD was impaired. Finally, pharmacological blockade of the degradation of anandamide and 2-arachidonylglycerol,
the two principal endocannabinoids restored fmr1-/y LTD to wild-type levels. These findings shed new light on the complex
influence of acetylcholine on excitatory synapses in the nucleus accumbens core and identify new substrates of the synaptic
deficits of Fragile X.
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■ INTRODUCTION
Acetylcholine is a major neurotransmitter and modulator in the
CNS acting via ionotropic nicotinic and metabotropic
muscarinic receptors. It is involved in a plethora of cognitive
and executive functions.1
Five distinct muscarinic acetylcholine receptor (mAChR)
subtypes (M1−M5) are expressed in the brain,
2,3 and
quantitative autoradiographic studies have demonstrated that
the striatum has one of the highest concentrations of
muscarinic receptors,4 highlighting the importance of muscar-
inic signaling in the basal ganglia. The role of dorso-striatal
cholinergic transmission in the control of voluntary movement
is well established.5 The ventral part of the striatum, the nucleus
accumbens, has been conceptualized as the “gatekeeper” of the
basal ganglia, because it is ideally positioned to integrate signals
originating from limbic and cortical areas and modulate reward-
related motor output.6 The accumbens has been extensively
studied in the context of drug abuse and addiction related
behaviors.7,8 More recently, its role in rewarding social
behaviors and social interactions has been highlighted.9−11
Muscarinic and nicotinic receptors in the accumbens are
necessary for the acquisition of appetitive tasks,12 food and drug
satiety.13 How cholinergic inputs modulate glutamatergic
synaptic transmission onto medium spiny neurons (MSN)
remains poorly understood.
M1 mAChR activation triggers long-term depression (LTD)
in the perirhinal cortex,14 the visual cortex,15 the hippo-
campus,16,17 the prefrontal cortex18 as well as axonal signal
processing.19 In contrast to the dorsal striatum, how mAChR
modulate synaptic plasticity in the accumbens remains largely
unknown.
Cholinergic dysfunction has been implicated in the
pathophysiology of schizophrenia, mood disorders, as well as
neurodegenerative disorders including Alzheimer’s and Parkin-
son’s diseases.1,20,21 Fewer studies have addressed the
implication of the cholinergic system in Fragile X syndrome
(FXS), the most common monogenetic cause of inherited
intellectual disability and a leading cause of autism.22−24 The
disease is caused by mutation of a single X-linked gene called
fmr1.25 The Fragile X mental retardation protein (FMRP) is a
71 kDa protein which regulates the transport and translation of
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more than 850 mRNAs in the brain and especially in
synapses.26−28 In humans with FXS, the loss of FMRP results
in a variety of neurological symptoms widely associated with
dysfunctional synaptic plasticity in critical brain regions such as
the cortex, hippocampus, and amygdala.29,30 In the fmr1-/y
mice model of FXS, structural and functional deficits have been
reported in multiple brain areas, most notably the hippo-
campus, the cortex but also the striatum and accumbens.31−35
Although acetylcholine plays a key role in arousal and reward
and FXS patients commonly show symptoms in associated
behaviors,29,36 how acetylcholine-accumbens plasticity is
affected in fmr1-/y mice is currently not known.
Here we used pharmacological methods to explore acetylcho-
line-dependent synaptic plasticity and its underpinnings in the
accumbens core region of wild-type and fmr1-/y mice. We
report that two types of M1 mAChR-mediated LTD and one
long-term potentiation (LTP) cohabit at excitatory synapses
onto accumbens core MSN. Moderate pharmacological
activation of M1 mAChR induces both a TRPV1-mediated
LTD and a potentiation of NMDAR, two phenomena that
occlude mutually. In response to strong activation, M1 mAChRs
induce a CB1R-mediated retrograde LTD. Finally, we show
that CB1R-mediated but not TRPV1-mediated M1-LTD was
affected in fmr1-/y mice and that pharmacological blockade of
the degradation of anandamide and 2-arachidonylglycerol, the
two principal endocannabinoids (eCBs), restored LTD in the
Fragile X mouse model.
The results provide a previously unidentified link between
M1 mAChR-mediated accumbal synaptic plasticity and
cognitive dysfunction in Fragile X and suggest the cholinergic
system as a novel therapeutic target.
■ RESULTS
Direct Activation of Muscarinic M1 Receptors Induces
LTD in the Accumbens Core. Acute cholinergic stimulation
induces synaptic plasticity in several cortical areas.18,37 Striatal
medium spiny neurons (MSN) receive cholinergic innervation
from the brain stem38 and local giant cholinergic interneur-
ons.39 We first tested the hypothesis that G-protein coupled
muscarinic acetylcholine receptors (mAChRs) can modulate
excitatory synapses in the accumbens.
Recording field EPSPs from MSN in the accumbens core, we
first challenged slices from adult wild-type mice with brief (10
min) applications of the large spectrum muscarinic agonist
Carbachol. Figure 1A shows the individual field responses in
two representative experiments. Bath perfusion with 10 μM
Carbachol induced a short lasting and fully reversible
depression (STD), which returned to baseline levels after 20
min. In contrast, bath-perfusion of 100 μM Carbachol induced
a sustained LTD of synaptic efficacy in the accumbens core.
Figure 1B summarizes the average field responses for the three
different concentrations tested. All three concentrations
induced significant STD in comparison to baseline response
(1 μM: 79.27 ± 5.373, p = 0.006, n = 8; 10 μM: 52.89 ± 3.730,
p < 0.0001, n = 9; 100 μM: 42.22 ± 3.249, p < 0.0001, n = 13;
one-sample t test). There was a concentration-dependent
difference in the amount of STD (one-way ANOVA p < 0.0001
with Holm-Sidak’s multiple comparisons test: 1 μM vs 10 μM p
= 0.0002; 1 μM vs 100 μM p < 0.0001; 1 μM vs 10 μM; 10 μM
vs 100 μM p = 0.0216). From our results, it is clear that LTD
was triggered solely in response to the highest dose of
Carbachol (1 μM: 96.48 ± 6.677, p = 0.6146; 10 μM: 107.3 ±
4.661, p = 0.1555; 100 μM: 76.90 ± 4.190, p < 0.0001; one-
sample t test). Figure 1C shows the lack of correlation between
Figure 1. Direct pharmacological activation of M1 AChR triggers STD and LTD in the nucleus accumbens core. (A) Representative field recording
showing the effects of 10 μM and 100 μM Carbachol. The lowest dose (10 μM) induced a strong but transient depression of synaptic responses
(short-term depression, STD). The highest concentration of Carbachol (100 μM) induced a robust LTD. (B) Averaged fEPSPs for three different
Carbachol concentrations (1 μM, n = 8; 10 μM n = 9; 100 μM n = 13). All three concentrations induced STD but only 100 μM Carbachol induced
LTD. (C) Pearson’s correlation showed no dependence of LTD magnitude on STD. (D) 100 μM Carbachol mediated LTD was highly sensitive to
the M1 antagonist VU0225035. n = 12, *P < 0.05.
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the magnitude of STD and LTD at all three concentrations of
Carbachol tested (1 μM p = 0.8653; 10 μM p = 0.4967; 100
μM p = 0.2187; Pearson’s correlation).
In the medial and prelimbic prefrontal cortices, Carbachol
induced LTD is mediated by M1 mAChR.
18,37,40 Thus,
accumbens slices were incubated with the M1 specific receptor
antagonist VU0225035 (10 μM). Figure 1D shows that LTD
was inhibited by the M1 mAChR antagonist (92.92 ± 4.292, n =
12, p = 0.1270, one-sample t test), showing that activation of
M1 mAChR induces LTD in the accumbens core as
demonstrated previously in the prefrontal cortex.18,37,40
Potentiated Synaptic NMDA Currents Mask “Low
Carbachol” LTD. In contrast with previous studies, including
one from our laboratory demonstrating LTD induced by low
concentrations of Carbachol in the prefrontal cortex
(PFC),18,40 we were surprised to observe that bath application
of 10 μM Carbachol was not sufficient to induce LTD. Such a
discrepancy could be due to low M1R expression or poor M1R-
coupling efficiency to downstream effectors or result from
multiple compensating/antagonizing M1R-mediated synaptic
effects. Noteworthy, activation of M1R potentiates NMDAR
currents and offsets LTD in the dorsal striatum.5,41 To test if a
similar process occurs in the accumbens core, we simply
recorded NMDAR-mediated fEPSP in artificial cerebrospinal
fluid (ACSF) containing 0 Mg2+ and 100 μM CNQX to block
ionotropic glutamate receptors fast synaptic potentials (i.e.,
mediated by AMPAR/KAR). fEPSP recordings were chosen to
allow for the direct comparison with our LTD experiments and
their robustness to pharmacological treatments. Figure 2A
shows the average NMDAR field recordings, and the inset
illustrates two averaged field responses (pre- and post-
Carbachol application): 10 μM Carbachol induced a rapid
short-term depression of NMDAR mediated fEPSPs (66.23 ±
4.884, n = 5, p = 0.0023, one-sample t test; Figure 2B) followed
by a LTP after drug washout (137 ± 12.6, p = 0.0425, one-
sample t test), whereas 100 μM Carbachol also induced rapid
short-term depression of NMDAR fEPSPS (43.58 ± 10.67, n =
8, p = 0.2156, one-sample t test) followed by a trend toward
LTD after drug washout (81.22 ± 13.79, p = 0.2156, one-
sample t test). Thus, NMDAR-mediated synaptic responses in
the accumbens are potentiated by mAChR, as previously
reported in the dorsal striatum.5,41
We hypothesized that LTP of NMDAR synaptic potentials
might mask the LTD of AMPAR fEPSPs. We reasoned that
NMDAR antagonism could unmask LTD in slices perfused
with low Carbachol. In support of this scenario, bath perfusion
of 10 μM Carbachol in the presence of the NMDAR antagonist
D-AP5 (50 μM) now induced a significant LTD (85.28 ±
3.365, n = 15, p = 0.0006, one-sample t test). This LTD was
blocked in accumbens slices incubated with the M1 specific
receptor antagonist VU0225035 (10 μM) (94 ± 3.103, n = 8, p
= 0.1126, one-sample t test, Figure 2B).
Together our data show that moderate activation of M1
mAChR with 10 μM Carbachol induces concomitant AMPAR
LTD and NMDAR LTP. Although “low Carbachol” largely
modulates AMPAR and NMDAR function, the change in
synaptic transmission can only be unmasked by blocking
NMDAR.
TRPV1 Receptors, not CB1R, Mediate “Low Carba-
chol” LTD. Different LTD pathways allow a single neuron to
engage either presynaptic CB1R or postsynaptic TRPV1
receptors.42 It has been long established that M1 mAChR can
engage the production of eCBs to consequently modulate short
and long-term synaptic plasticity.43,44 In the bed nucleus stria
terminalis42 and also the accumbens, eCB engage presynaptic
CB1R and/or postsynaptic TRPV1R depending on cell type
and stimulation patterns.45,46
Hence, we explored the locus of LTD expression and the
mechanism of the low Carbachol LTD. A series of experiments
was performed in the presence of D-AP5 to block NMDAR and
unmask LTD (Figure 3). We found that induction of low
Carbachol LTD was abolished in slices incubated with the
selective TRPV1 receptor antagonist AMG9810 (98.21 ±
5.984, n = 5, p = 0.7801, Student’s t test; Figure 3). However,
low Carbachol LTD was unaffected by the CB1R antagonist
SR141716A (83.64 ± 5.932, n = 10, p = 0.0220, Student’s t test;
Figure 3C). We verified the locus of LTD by simply quantifying
the changes in the paired-pulse ratio from the field excitatory
responses (Figure 3A, lower trace). The paired-pulse ratio
quickly returned to baseline (p = 0.5818, Student’s t test),
pointing toward a postsynaptic expression mechanism of LTD
expression. Taken together, these data strongly suggest that low
Carbachol induces a postsynaptic LTD mediated by TRPV1
receptors.
“High Carbachol” LTD Depends on Endocannabinoid
Retrograde Signaling and CB1R. We next examined
whether CB1R and/or TRPV1 were responsible for high
Carbachol/M1 mAChR LTD. The CB1R antagonist SR14176A
(5 μM) efficiently blocked high Carbachol LTD (96.44 ±
5.061, n = 7, p = 0.5082, Student’s t test Figure 4) whereas the
TRPV1 receptor antagonist AMG9810 (10 μM) did not
prevent the expression of LTD (89.38 ± 1.966, n = 7, p =
Figure 2. NMDAR modulates mAChR-induced synaptic plasticity. (A)
Averaged field recordings of NMDAR responses. In response to bath-
application of 10 μM Carbachol, transient depression was followed by
a marked LTP of NMDAR-fEPSP. In response to bath-application of
100 μM Carbachol, the transient depression was followed by a trend
toward LTD of NMDAR-fEPSP. Inset: representative field response
before and after 10 μM Carbachol application. (B) Average field
recordings of AMPAR responses. Ten μM Carbachol mediated LTD
was unmasked after blocking NMDAR with dAPV. This LTD was
blocked with the M1 specific receptor antagonist VU0225035 (50
μM). *p < 0.05.
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0.0017; Student’s t test Figure 4). We conclude that high
Carbachol LTD requires CB1R, not TRPV1. In the extended
amygdala and accumbens, both mGluR1 and mGluR5
participate to eCB-LTD.42,46 In striking contrast, neither the
mGluR5 specific antagonist MPEP nor the mGluR1 specific
antagonist CPCCoEt prevented from high Carbachol LTD (p =
0.0142; n = 8, Student’s t test, data not shown).
We verified that high Carbachol LTD had a presynaptic locus
of expression as typically expected if CB1R were implicated.45
Indeed, high Carbachol LTD was paralleled by a significant
enhancement of the paired-pulse ratio (p = 0.0419, Student’s t
test, Figure 4A, lower trace). Together these data suggest that
M1 mAChR LTD induced by high Carbachol is mediated by
eCB acting at presynaptic CB1R.
CB1R-Mediated but Not TRPV1-Mediated LTD Is
Impaired in fmr1-/y Mice. The postsynaptic mGluR5/eCB
signaling complex is impaired at accumbens synapses of fmr1-/y
mice.31,32 M1 mAChR and mGluR1/5 are Gq/11-protein
coupled receptors with common downstream effectors
including eCB.44 Having established that activation of M1
mAChR receptors triggers eCB-mediated LTD via CB1R or
TRPV1R, we next tested low and high Carbachol LTD in adult
fmr1-/y mice. As for Figure 3, the experiments to characterize
low Carbachol/TRPV1R- dependent LTD were performed in
the presence of D-AP5 to block NMDAR and unmask LTD.
The data show that low Carbachol/TRPV1R-dependent LTD
was readily induced in fmr1-/y mice (84.21 ± 3.9, n = 5, p =
0.0155, Student’s t test; Figure 5A) and not different from
controls (p = 0.743, one-way ANOVA).
On the contrary, high Carbachol/CB1R-mediated LTD was
not abolished (94.55 ± 2.084, n = 17, p = 0.0187, Student’s t
test) but significantly reduced in fmr1-/y mice compared to
WT littermates (Figure 5B, p = 0.0029, unpaired t test).
In the fmr1-/y mouse model, enhancing 2-AG levels by
blocking its degradation with the selective monoacylglycerol
lipase inhibitor JZL184, normalized synaptic and behavioral
impairments.32 We attempted a similar strategy to rescue
deficient high Carbachol LTD in fmr1-/y. Indeed, blocking 2-
AG degradation with JZL184 restored high Carbachol LTD in
Figure 3. Postsynaptic TRPV1 mediates low carbachol LTD. (A) Averaged field recordings of AMPAR responses showing that preincubation with
the TRPV1R antagonist AMG 9810 (10 μM) completely prevented the induction of LTD by 10 μM Carbachol. (B) Example traces of average field
response before and after Carbachol application. (C) Summary bar graph of the pharmacological experiments characterizing low (10 μM) LTD.
LTD was blocked by the application of the TRPV1R antagonist AMG9810 (10 μM) but not the CB1R antagonist SR141716a (5 μM). Error bars
represent mean ± SEM. §p < 0.05, Student’s t test. The number in each bar indicates the number of experiments.
Figure 4. Presynaptic CB1R mediates high carbachol LTD. (A) Averaged field recordings of AMPAR responses. In slices preincubated with the
CB1R antagonist SR141716A (5 μM), 100 μM Carbachol induced STD but not LTD. (B) Example traces of average field response before and after
Carbachol application. (C) Summary bar graph of all pharmacological experiments characterizing the effects of high-Carbachol: LTD was blocked by
the application of the CB1R antagonist SR141716a but not by the TRPV1R antagonist AMG9810 (10 μM). Error bars represent mean ± SEM. *p <
0.05, unpaired t test; §p < 0.05, Student’s t test. The number in each bar indicates the number of experiments.
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fmr1-/y mice (Figure 5C, 76.68 ± 4.292, n = 15, p < 0.001,
Student’s t test).
The two principal signaling eCBs, anandamide and 2-
arachidonoylglycerol (2-AG) are thought to have different
targets. While anandamide activates CB1R and TRPV1R, 2-AG
is thought to mostly engage CB1R.47−49 In fmr1-/y mice,
impaired social interactions and avoidance are improved by
URB-597,50,51 suggesting that elevation of anandamide levels
can be beneficial to alleviate from certain Fragile X behavioral
symptoms. We tested a similar strategy to relieve the synaptic
deficits we had uncovered. In favor of this idea, we found that
when accumbens slices from fmr1-/y mice were incubated with
URB597, high Carbachol treatment induced a LTD indis-
tinguishable from that of wild-type littermates (Figure 5C,
74.33 ± 4.041, n = 13, <0.001, Student’s t test). The LTD
rescued by incubation with URB597 was not affected by
incubation with the TRPV1 antagonist AMG9810 (59.19 ±
5.434, p = 0.0017, <0.001, Student’s t test) but by incubation
with the CB1antagonist SR141716A (96.87 ± 8.736, Student’s t
test). These results demonstrate that enhanced anandamide
rescues high Carbachol LTD via enhancing CB1R but not
TRPV1 signaling.
Neither selective monoacylglycerol lipase inhibitor JZL184
nor the FAAH inhibitor URB-597 had a significant effect on
high Carbachol LTD in wildtype littermates (see Supplemen-
tary Figure 1).
■ DISCUSSION
The principal results of this study are (1) that, at accumbens
core synapses, M1 mAChR control two forms of endocanna-
binoid mediated LTD that differ in their signaling pathways and
locus of depression and (2) that lack of FMRP expression
selectively impairs CB1R-mediated plasticity.
Low concentration of Carbachol engaged TRPV1 receptors
and caused a reduction in postsynaptic AMPAR. These results
are in agreement with a previous report showing that activation
of TRPV1 via the endocannabinoid anandamide induces LTD
in the accumbens.46 Indeed, anandamide has been demon-
strated to be an endogenous TRPV1 agonist.52
It is important to note that the low Carbachol LTD was
unmasked when blocking NMDAR. Several mechanisms could
explain the mAChR-mediated synaptic potentiation of
NMDAR in accumbens MSN. First, Calabresi et al. have
demonstrated that elevation of endogenous acetylcholine
increases the conductance of NMDAR.5 Second, M1-dependent
inhibition of SK channels boosts synaptic potentials.41
Although we cannot unequivocally determine which of these
mechanisms mediates NMDAR potentiation, we clearly
demonstrate that blocking this potentiation unmasks “low
Carbachol” LTD.
The high Carbachol LTD required CB1R-mediated
presynaptic inhibition of glutamate release. In the nucleus
accumbens core, eCB-LTD implicates postsynaptic mGluR5,
the production of 2-AG that retrogradely activates presynaptic
CB1R.44,45 Both mGluR5 and M1 mAChR are Gq-coupled
receptors, that engage similar downstream plasticity mecha-
nisms.53 M1 mAChR regulate inhibitory and excitatory synapses
via 2-AG and CB1R.54−58 Thus, the current data add to the
growing list of central synapses where 2-AG is the principal
mediator of eCB mediated GPCR synaptic plasticity.
Whether low and high Carbachol LTD are induced
simultaneously in response to strong M1 mAChR stimulation
or whether they exclude each other is not completely clear: the
slight decrease in LTD after application of a TRPV1 antagonist,
which would demonstrate a summation of plasticity did not
reach statistical significance (see Figure 4C). The two forms of
LTD could engage different signaling pathways by recruiting
anandamide for postsynaptic LTD and 2-AG for presynaptic
LTD. Indeed, that both eCBs are engaged in M1-LTD is
supported by the present observation that LTD in fmr1-/y mice
is rescued by blocking the degradation of either anandamide or
2-AG. How the activation of M1 can lead to the engagement of
two different endocannabinoid signaling pathways remains to
be determined.
Although the production of both endocannabinoids has been
shown to depend on GPCR activation, this production can also
be state dependent, e.g., depend on activation of voltage gated
calcium channels59 which could bias the production of one eCB
over the other depending on the degree of activation. The two
forms of plasticity could also be expressed separately in the two
subtypes of medium spiny neurons (i.e., D1R- or D2R-
expressing). Although subtype specific synaptic plasticity
mechanisms have been reported with various induction
Figure 5. Altered M1R-LTD in fmr1-/y mice. (A) Summary graph
showing that low Carbachol-LTD is intact in fmr1-/y mice. (B)
Summary graph showing that high Carbachol-LTD is abolished in
fmr1-/y mice. (C) Bar graph of pharmacological experiments (mean
values of minutes 50−59). The preincubation with URB597 and
JZL184 could rescue LTD. LTD rescued by incubation with URB597
could be blocked by SR41716A but not AMG9810. Error bars
represent mean ± SEM. *p < 0.05, unpaired t test; §p < 0.05, Student’s
t test. The number in each bar indicates the number of experiments.
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protocols59,60 the animal models used have been ques-
tioned.61−64 The unimodal distribution of LTD observed in
patch clamp experiments does not support the idea that CB1R
and TRPV1R are expressed in different MSN subtypes
(Supplementary Figure 2).
In fmr1-/y mice, only high CB1R-mediated LTD was ablated,
and TRPV1R-mediated LTD was normal. Inhibition of either
2-AG or anandamide degradation restored CB1R-LTD. Our
results are compatible with recent reports showing that
blocking the FAAH inhibitor with URB-597 improves perform-
ance in the passive avoidance test and social impairments in
fmr1-/y mice50,51
The complex regulation of synaptic plasticity in the
accumbens by M1 mAChR supports the idea that the
cholinergic system is a substrate of arousal and emotional
deficits observed in Fragile X.
■ METHODS
Animals. Animals were treated in compliance with the European
Communities Council Directive (86/609/EEC) and the United States
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. All animals were housed with 12 h light/dark
cycles and access to food and water ad libitum.
Slice Preparation. Adult male fmr1-/y mice on a C57Bl6/J genetic
background aged between 60 and 95 postnatal days were used, with
wild-type littermates and C57Bl6/J mice purchased from Janvier
Laboratories France used as control group.32 They were anesthetized
with isoflurane and decapitated according to institutional regulations.
The brain was sliced (300 μm) in the coronal plane with a vibratome
(Integraslice, Campden Instruments, Loughborough, UK) in a
sucrose-based solution at 4 °C (in mM: 87 NaCl, 75 sucrose, 25
glucose, 2.5 KCl, 4 MgCl2, 0.5 CaCl2, 23 NaHCO3 and 1.25
NaH2PO4). Immediately after cutting, slices were stored for 1 h at 32
°C in a low calcium artificial cerebrospinal fluid (low Ca2+ ACSF) that
contained (in mM) 130 NaCl, 11 glucose, 2.5 KCl, 2.4 MgCl2, 1.2
CaCl2, 23 NaHCO3, 1.2 NaH2PO4, and was equilibrated with 95% O2/
5% CO2. Slices were maintained at room temperature until the time of
recording.
Electrophysiology. Field potential recordings were made in
coronal slices containing the accumbens core as previously
described.31,45 Recordings were made in the medial ventral accumbens
core close to the anterior commissure.31,45
For recording, slices were placed in the recording chamber and
superfused (1.5−2 mL/min) with ACSF (same as low Ca2+ ACSF with
the following exception: 2.4 mM CaCl2 and 1.2 mM MgCl2). All
experiments were done at 25 °C. Picrotoxin (100 μM) was added to
the superfusion medium to block gamma-aminobutyric acid type A
(GABA-A) receptors. All drugs were added at the final concentration
to the superfusion medium (see Table 1).
For field excitatory postsynaptic potential (fEPSP), the recording
pipet was filled with ACSF and afferents were stimulated with a glass
electrode filled with ACSF and placed ∼200 μm in the dorsal-medial
direction of the recording pipet. The stimulus intensity was adjusted
around 80% of maximal intensity after performing an input-output
curve (baseline fEPSP amplitudes ranged between 0.15 mV and 0.4
mV). Stimulation frequency was set at 0.1 Hz.
Recordings were performed with an Axopatch-200B amplifier (Axon
Instrument, Molecular Devices, Sunnyvale, CA). Data were low-pass
filtered at 2 kHz, digitized (10 kHz, DigiData 1440A, Axon
Instrument, Molecular Devices, Sunnyvale, CA), collected using
Clampex 10.2, and analyzed using Clampfit 10.2 (Axon Instrument,
Molecular Devices, Sunnyvale, CA). Both fEPSPs’ area and amplitude
were analyzed.
Drugs. All drugs were added at final concentration to the
superfusion medium (see Table 1 for details).
Data Acquisition and Analysis. The magnitude of plasticity was
calculated 40−44 min after the plasticity protocols as percentage of
baseline responses. Statistical analysis of data was performed with
GraphPad Prism (GraphPad Software Inc., La Jolla, CA). All values are
given as mean ± standard error. N indicates the number of
experiments. At least 3−12 animals were used for each single
experimental condition. The Shapiro−Wilk test confirmed the normal
distribution of data sets. Therefore, depending on the experimental
condition, statistical differences were assessed using t tests and one-
way ANOVA post hoc tests. A confidence level of P < 0.05 was
considered significant.
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NIMH 5 45 20
AMG9810 (TRPV1R
antagonist)
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